Literature DB >> 31664624

Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy.

Shih-Chun Cheng1,2,3, Kueian Chen1,2,3, Chih-Yung Chiu4,5, Kuan-Ying Lu1,2,3, Hsin-Ying Lu1,2,3, Meng-Han Chiang2,3, Cheng-Kun Tsai2,3, Chi-Jen Lo6, Mei-Ling Cheng3,6,7, Ting-Chang Chang8, Gigin Lin9,10,11.   

Abstract

INTRODUCTION: Endometrial cancer (EC) is one of the most common gynecologic neoplasms in developed countries but lacks screening biomarkers.
OBJECTIVES: We aim to identify and validate metabolomic biomarkers in cervicovaginal fluid (CVF) for detecting EC through nuclear magnetic resonance (NMR) spectroscopy.
METHODS: We screened 100 women with suspicion of EC and benign gynecological conditions, and randomized them into the training and independent testing datasets using a 5:1 study design. CVF samples were analyzed using a 600-MHz NMR spectrometer equipped with a cryoprobe. Four machine learning algorithms-support vector machine (SVM), partial least squares discriminant analysis (PLS-DA), random forest (RF), and logistic regression (LR), were applied to develop the model for identifying metabolomic biomarkers in cervicovaginal fluid for EC detection.
RESULTS: A total of 54 women were eligible for the final analysis, with 21 EC and 33 non-EC. From 29 identified metabolites in cervicovaginal fluid samples, the top-ranking metabolites chosen through SVM, RF and PLS-DA which existed in independent metabolic pathways, i.e. phosphocholine, malate, and asparagine, were selected to build the prediction model. The SVM, PLS-DA, RF, and LR methods all yielded area under the curve values between 0.88 and 0.92 in the training dataset. In the testing dataset, the SVM and RF methods yielded the highest accuracy of 0.78 and the specificity of 0.75 and 0.80, respectively.
CONCLUSION: Phosphocholine, asparagine, and malate from cervicovaginal fluid, which were identified and independently validated through models built using machine learning algorithms, are promising metabolomic biomarkers for the detection of EC using NMR spectroscopy.

Entities:  

Keywords:  Biomarkers; Endometrial neoplasms; Magnetic resonance spectroscopy; Metabolomics

Mesh:

Substances:

Year:  2019        PMID: 31664624     DOI: 10.1007/s11306-019-1609-z

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  28 in total

1.  Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.

Authors:  Tamara Knific; Joško Osredkar; Špela Smrkolj; Irena Tonin; Katja Vouk; Andrej Blejec; Snježana Frković Grazio; Tea Lanišnik Rižner
Journal:  Gynecol Oncol       Date:  2017-07-21       Impact factor: 5.482

2.  Atypical Glandular Cells of Endometrial Origin and the Risk of Endometrial Cancer.

Authors:  Xuezhi Jiang; Charmaine Anderson; Kathryn E Sharpless; Jessica White; Chevon Alderson; John Demko; Bernice Robinson-Bennett; Peter F Schnatz
Journal:  J Low Genit Tract Dis       Date:  2015-07       Impact factor: 1.925

3.  Applying SWATH Mass Spectrometry to Investigate Human Cervicovaginal Fluid During the Menstrual Cycle.

Authors:  Kanchan Vaswani; Keith Ashman; Sarah Reed; Carlos Salomon; Suchismita Sarker; Jose A Arraztoa; Alejandra Pérez-Sepúlveda; Sebastian E Illanes; David Kvaskoff; Murray D Mitchell; Gregory E Rice
Journal:  Biol Reprod       Date:  2015-06-24       Impact factor: 4.285

4.  Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis.

Authors:  Caixia Wang; Heyu Chen; Mingchao Zhang; Jie Zhang; Xunbin Wei; Weihai Ying
Journal:  Cancer Lett       Date:  2016-05-06       Impact factor: 8.679

Review 5.  Discovery of biomarkers for endometrial cancer: current status and prospects.

Authors:  Tea Lanišnik Rižner
Journal:  Expert Rev Mol Diagn       Date:  2016-11-21       Impact factor: 5.225

6.  Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway.

Authors:  Sebastian Trousil; Patrizia Lee; David J Pinato; James K Ellis; Roberto Dina; Eric O Aboagye; Hector C Keun; Rohini Sharma
Journal:  Cancer Res       Date:  2014-09-29       Impact factor: 12.701

7.  Development of a Sampling Collection Device with Diagnostic Procedures.

Authors:  Jhih-Yan Cheng; Mow-Jung Feng; Chia-Chi Wu; Jane Wang; Ting-Chang Chang; Chao-Min Cheng
Journal:  Anal Chem       Date:  2016-07-12       Impact factor: 6.986

8.  Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women.

Authors:  Yannick Audet-Delage; Lyne Villeneuve; Jean Grégoire; Marie Plante; Chantal Guillemette
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-12       Impact factor: 5.555

9.  Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid.

Authors:  Geert A A Van Raemdonck; Wiebren A A Tjalma; Edmond P Coen; Christophe E Depuydt; Xaveer W M Van Ostade
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

10.  Identifying metabolite markers for preterm birth in cervicovaginal fluid by magnetic resonance spectroscopy.

Authors:  Emmanuel Amabebe; Steven Reynolds; Victoria L Stern; Jennifer L Parker; Graham P Stafford; Martyn N Paley; Dilly O C Anumba
Journal:  Metabolomics       Date:  2016-03-08       Impact factor: 4.290

View more
  10 in total

1.  Multi-Omic Profiling of Multi-Biosamples Reveals the Role of Amino Acid and Nucleotide Metabolism in Endometrial Cancer.

Authors:  Runqiu Yi; Liying Xie; Xiaoqing Wang; Chengpin Shen; Xiaojun Chen; Liang Qiao
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

2.  Research on the Guiding Effect of CTCs on Postoperative Adjuvant Therapy for Patients with Early Stage Endometrial Cancer.

Authors:  Liguo Li; Huihui Zhai; Qiumei Zhang; Yuan Feng; Chunhui Yang; Hong Li; Hongfen He
Journal:  J Oncol       Date:  2022-05-31       Impact factor: 4.501

3.  A comparison of high-throughput plasma NMR protocols for comparative untargeted metabolomics.

Authors:  Nikolaos G Bliziotis; Udo F H Engelke; Ruud L E G Aspers; Jasper Engel; Jaap Deinum; Henri J L M Timmers; Ron A Wevers; Leo A J Kluijtmans
Journal:  Metabolomics       Date:  2020-05-01       Impact factor: 4.290

Review 4.  Metabolomics for Diagnosis and Prognosis of Uterine Diseases? A Systematic Review.

Authors:  Janina Tokarz; Jerzy Adamski; Tea Lanišnik Rižner
Journal:  J Pers Med       Date:  2020-12-21

5.  Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer.

Authors:  Kelechi Njoku; Amy E Campbell; Bethany Geary; Michelle L MacKintosh; Abigail E Derbyshire; Sarah J Kitson; Vanitha N Sivalingam; Andrew Pierce; Anthony D Whetton; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.575

6.  Grading of endometrial cancer using 1H HR-MAS NMR-based metabolomics.

Authors:  Agnieszka Skorupa; Michał Poński; Mateusz Ciszek; Bartosz Cichoń; Mateusz Klimek; Andrzej Witek; Sławomir Pakuło; Łukasz Boguszewicz; Maria Sokół
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

7.  A Crosstalk- and Interferent-Free Dual Electrode Amperometric Biosensor for the Simultaneous Determination of Choline and Phosphocholine.

Authors:  Rosanna Ciriello; Antonio Guerrieri
Journal:  Sensors (Basel)       Date:  2021-05-19       Impact factor: 3.576

Review 8.  Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer.

Authors:  Kelechi Njoku; Caroline J Sutton; Anthony D Whetton; Emma J Crosbie
Journal:  Metabolites       Date:  2020-07-31

Review 9.  Endometrial cancer-is our knowledge changing?

Authors:  Milena Králíčková; Vaclav Vetvicka; Antonio Simone Laganà
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

Review 10.  New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers.

Authors:  Jitka Holcakova; Martin Bartosik; Milan Anton; Lubos Minar; Jitka Hausnerova; Marketa Bednarikova; Vit Weinberger; Roman Hrstka
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.